3085 results for "Psilocybin"
Informed Consent in Psychedelic-Assisted Therapy.
Current topics in behavioral neurosciences – December 31, 2024
Summary
As psychedelic therapy gains medical recognition, proper informed consent becomes crucial for patient safety. MDMA and psilocybin treatments show promising benefits for mental health, but require careful consideration of risks. Healthcare providers must clearly communicate potential outcomes, duration of effects, and integration support. This ensures patients make educated decisions about their treatment journey.
Abstract
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymetham...
Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey
Journal of Psychoactive Drugs – December 24, 2024
Summary
Despite a strong preference for natural psychedelics, 67.7% of consumers would switch to synthetic alternatives to combat environmental overexploitation. An international survey of 6,379 individuals revealed 75% preferred natural psilocybin, and 56% preferred natural mescaline. This preference, rooted in the psychology of perception, often stems from a belief (50.8%) that natural origins impact psychological effects. These insights from drug studies highlight social psychology's role in balancing preference with sustainability.
Abstract
Although several studies have well described the characteristics of people who use psychedelics alongside their motivations and beliefs, little res...
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.
The lancet. Psychiatry – January 01, 2025
Summary
Psychedelic therapy is gaining momentum in mental health treatment, but how therapists work with patients during these sessions varies widely. A comprehensive analysis of 45 studies revealed significant inconsistencies in how psychological support is provided alongside substances like psilocybin, MDMA, and LSD. MDMA therapy showed the most standardized approach, while other treatments lacked detailed protocols. Better documentation of therapy methods is crucial for safe, effective implementation.
Abstract
Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic com...
Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Annual Review of Medicine – November 11, 2024
Summary
Breakthroughs in medicine offer new hope for major depressive disorder, a condition with an enormous global economic burden. Brexanolone and zuranolone, the first FDA-approved drugs for postpartum depression, signify a critical advancement in maternal mental health. These transformative therapies provide rapid relief for a vulnerable population. Psilocybin also shows promise for treatment-resistant depression, signaling a significant stride in psychiatry and psychology. Such innovations aim to reshape treatment, impacting identity and memory through effective therapy.
Abstract
Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our a...
Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
Journal of Psychoactive Drugs – November 06, 2024
Summary
Exclusive psychedelic microdosers, a subset of 2488 individuals from a survey of 6193 consumers, exhibit distinct demographics and substance use patterns. They are older (46.4 vs. 42.0 years), predominantly female (68.4% vs. 44.7%), and report less non-psychedelic substance use (3.8 vs. 4.7 substances) compared to those also using macrodoses. Most microdose multiple times monthly, often with psilocybin (74.5%) or LSD (34.4%), primarily for wellbeing (73.0%), though 64.6% don't test their substances.
Abstract
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described t...
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Journal of Psychoactive Drugs – November 06, 2024
Summary
A critical review of nine **psychedelics and drug studies** reveals a significant challenge for **medicine**: nearly 78% had poor **masking** success. This means participants often knew if they received the active **chemical compounds**—like psilocybin or LSD, often from **chemical synthesis**, or natural **alkaloids**—or a **placebo**. This complicates attributing positive changes in **psychology** to the drug alone. For instance, 60-75% of **placebo** groups in **clinical psychology** still showed large effect sizes. **Psychotherapists** must consider these unmasking influences.
Abstract
Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. Howe...
Australian psychologists' attitudes towards psychedelic‐assisted therapy and training following a world‐first drug down‐scheduling
Drug and Alcohol Review – November 05, 2024
Summary
Australian psychologists largely embrace psychedelic-assisted therapy for mental health, viewing it as a promising psychological intervention. A nonprobability snowball sampling of 20 psychologists revealed most had positive attitudes towards these compounds, often products of chemical synthesis and alkaloids like psilocybin. However, limited knowledge and concerns about efficacy and adverse experiences were noted. This highlights the critical need for comprehensive medical education and training to ensure competence in this evolving area of clinical psychology and applied psychology, integrating diverse academic research themes from psychedelics and drug studies.
Abstract
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the ...
Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada
PLoS ONE – October 24, 2024
Summary
Psychedelic clinics in Ontario are promoting psilocybin and other psychedelics for an astonishing 47 distinct medical conditions, often with insufficient scientific backing. An analysis of 10 clinic websites revealed only 2 out of 10 described potential risks. While 29 studies were cited for these medical prescriptions, most offered low-to-moderate "level 4" evidence, like case-series. This raises concerns for mental health patients seeking medicine, underscoring the need for transparent, high-quality information regarding psychedelic treatments in family medicine and psychiatry.
Abstract
Psychedelics, including ketamine, 3,4-Methyl enedioxy methamphetamine (MDMA), and psilocybin, have gained attention for their potential therapeutic...
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
BMC Medical Education – October 24, 2024
Summary
Australia has already approved MDMA and psilocybin for mental health, highlighting Europe's urgent need to advance medical education in psychedelic-assisted therapy. With USA trials in Phase III, Germany is poised to lead Europe in developing robust frameworks for integrating innovative Psychedelics and Drug Studies into Medicine. This includes defining ethical Psychotherapy Techniques and Applications, practitioner training, and regulatory oversight. Such infrastructure development aims to ensure proficient care, potentially reclaiming Europe's historical lead in Psychology and psychiatric innovation, as seen with Switzerland's 2014 reintroduction of MDMA and LSD for restricted medical use.
Abstract
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psyche...
Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Despite widespread use of psychedelics, only 28 drug-related deaths were linked to these substances across England, Wales, and Northern Ireland over 25 years. While each death is tragic, this remarkably low number supports psychedelics' relative safety profile. Most cases involved multiple substances, with LSD and psilocybin being most common. Adverse effects were typically connected to unsafe physical environments or toxicity from mixing drugs.
Abstract
Psychedelic drugs are increasingly visible in society once more, but their risks and adverse effects have received less attention than perhaps they...
Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task
Scientific Reports – October 18, 2024
Summary
Classic psychedelic compounds, including synthesized alkaloids like LSD and naturally occurring psilocybin, significantly boost emotional empathy. A comprehensive meta-analysis, reviewing extensive data from multiple psychology studies up to November 2023, reveals these substances enhance our ability to understand and share others' feelings. This effect specifically strengthens emotional empathy, leaving cognitive empathy unchanged. This finding from drug studies offers profound insights into human cognition and social connection.
Abstract
This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using th...
The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists
American Journal of Psychiatry – October 09, 2024
Summary
Substance use disorder (SUD) often goes untreated in Psychiatry, despite its significant impact. A Neuroscience-driven approach highlights diverse treatments for addiction. Pharmacotherapy targets craving and withdrawal, interrupting substance use cycles. Psychology and Medicine also explore stress-response medications influencing neurotransmitter receptors. Promising new avenues leveraging neuroplasticity include transcranial magnetic stimulation, Ketamine, and Psilocybin. These Psychedelics and Drug Studies offer innovative strategies for substance abuse, informing comprehensive care.
Abstract
Substance use disorder (SUD) is common in psychiatric patients and has a negative impact on health and well-being. However, SUD often goes untreate...
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
European Addiction Research – September 25, 2024
Summary
Psychedelics offer compelling new hope for treating addiction. A comprehensive review spanning 40 years of Psychedelics and Drug Studies highlights their therapeutic potential in medicine and psychiatry. Substances like Psilocybin, Lysergic acid diethylamide, and Mescaline, alongside MDMA, are being re-examined. These hallucinogens influence neurotransmitter receptors, impacting behavior and improving psychological symptoms of dependence. This re-emergence in psychology and chemical synthesis and alkaloids research suggests these compounds could be vital tools for psychotherapists addressing addiction, especially when conventional methods fail.
Abstract
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-2...
Exploring the regulatory framework of psychedelics in the US & Europe.
Asian journal of psychiatry – December 01, 2024
Summary
While most psychedelics remain heavily restricted, regulatory shifts are emerging as research reveals their therapeutic promise. The US and EU are developing frameworks to evaluate substances like psilocybin, LSD, and MDMA for mental health treatment. Ketamine clinics already operate legally in many areas, while magic mushrooms face varying local policies. New laws aim to balance patient access with safety controls.
Abstract
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic...
Tags
CCNP Innovations in Neuropsychopharmacology Award
Journal of Psychiatry and Neuroscience – September 19, 2024
Summary
Psychedelics are profoundly reshaping mental health treatment, offering a novel psychiatric framework. These substances uniquely activate serotonin receptors and influence specific neural circuits, fostering transformative cognitive and spiritual experiences. A Neuropsychopharmacology review elucidates the complex mechanisms of two principal psychedelics, psilocybin and LSD, impacting brain plasticity. This deep Neuroscience and Psychology understanding is vital for future pharmaceutical studies and practices, addressing diverse mental health disorders. Such insights could even extend to conditions like Attention Deficit Hyperactivity Disorder, integrating brain, mind, and spirituality.
Abstract
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last ...
Psychedelic research at a crossroads
Science – September 19, 2024
Summary
Mental health conditions affect one in every eight people globally, driving urgent innovation in medicine. Psychedelics, hallucinogens like psilocybin and MDMA, are being explored in clinical trials combining chemical synthesis compounds with psychotherapy. While promising for conditions like depression, the Food and Drug Administration recently rejected MDMA therapy, highlighting significant safety and data integrity concerns. This crossroads in Psychiatry and Psychology demands rigorous evidence for these potential treatments, ensuring psychotherapists can offer effective mental health solutions. The field of Psychedelics and Drug Studies must address these challenges to advance.
Abstract
There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat thi...
Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use
Journal of Psychoactive Drugs – September 19, 2024
Summary
Clients in naturalistic psychedelic-assisted therapy often report positive outcomes, even with practitioners outside traditional regulation. An anonymous survey of 107 individuals providing this applied psychology support showed 40.2% held a license, while 44.9% lacked a relevant graduate degree. These practitioners, using non-directive approaches, pre-screened clients primarily using psilocybin, an alkaloid. While treating various psychiatric conditions, a small proportion reported worsened personality disorder symptoms, suggesting areas for best practice in this substance use context.
Abstract
Psychedelic-assisted therapy (PAT) has shown preliminary efficacy for psychiatric and physical health conditions. Although some people report natur...
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – September 07, 2024
Summary
Classical hallucinogens like Psilocybin and Mescaline significantly reduce inflammation in preclinical animal studies. A systematic review of 40 articles, drawn from databases including CINAHL, MEDLINE, PsycINFO, and Web of Science, explored the pharmacology of these tryptophan-derived psychedelics. Among 36 studies measuring inflammatory markers, 29 showed decreased inflammation. However, immune cell activity was mixed across 10 studies. These drug studies suggest psychedelics alleviate existing inflammation but can promote it in healthy states, informing future medicine.
Abstract
Emerging evidence suggests that classical psychedelics possess immunomodulatory and anti-inflammatory properties; however, these effects are yet to...
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money
Annual Review of Psychology – August 02, 2024
Summary
Psychedelics show therapeutic potential in emerging drug studies. Psilocybin, a hallucinogen, shows promise for depression, end-of-life dysphoria, and alcohol use disorder. MDMA (Ecstasy) is being explored for PTSD. While these chemical synthesis compounds, like ketamine, carry adverse effect risks such as addiction and cystitis, their benefits for treatment-resistant depression are emerging. Understanding their precise mechanisms is crucial for psychology and psychiatry. Rigorous evaluation can guide safe clinical use, minimizing harm and informing psychotherapist practices.
Abstract
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is st...
Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.
Current topics in behavioral neurosciences – July 31, 2024
Summary
While generally safer than many recreational substances, psychedelics like LSD and psilocybin can profoundly alter consciousness through unique interactions with brain serotonin systems. Their classification includes three main types: phenethylamines, tryptamines, and ergolines. Though showing promise in mental health treatment, these substances carry risks of anxiety, dissociation, and psychological harm, particularly when combined with other drugs or used improperly.
Abstract
Psychedelics are a group of substances within the heterogeneous class of hallucinogenic drugs. Via binding to the serotonin (5-HT) 2A receptor, psy...
Toxicology and Pharmacological Interactions of Classic Psychedelics.
Current topics in behavioral neurosciences – July 24, 2024
Summary
Classic psychedelics like LSD and psilocybin show remarkably low physical toxicity, even at high doses. Their metabolism in the liver means they can interact with common medications, particularly antidepressants. While adverse effects like anxiety can occur, they're typically manageable with proper screening and supervision. Understanding these interactions helps ensure safe therapeutic use.
Abstract
As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacologica...
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
CNS drugs – October 01, 2024
Summary
Psychedelic medicines show promising results in treating addiction, with success rates significantly higher than traditional methods. Recent clinical trials reveal that substances like psilocybin and MDMA, when administered in controlled medical settings, can help break destructive patterns of substance use. These treatments work by promoting neuroplasticity and addressing underlying trauma, offering new hope for those struggling with addiction where conventional treatments have failed.
Abstract
Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, includi...
Innovative and Emerging Treatments for Anorexia Nervosa
FOCUS The Journal of Lifelong Learning in Psychiatry – July 01, 2024
Summary
Traditional psychological intervention and medicine often fall short for anorexia nervosa, a severe eating disorder. Psychiatry is exploring novel strategies, including brain stimulation techniques like vagus nerve stimulation and transcranial magnetic stimulation. Initial investigations also show promise for psilocybin and cannabidiol as potential treatments. These early findings, spanning clinical psychology and behavioral medicine, underscore an urgent need for robust clinical trials to improve patient outcomes.
Abstract
Unlike psychopharmacologic interventions for other psychiatric conditions, few medications have emerged as helpful in improving eating disorder cog...
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
The International journal on drug policy – August 01, 2024
Summary
A groundbreaking international survey reveals that personal growth, not recreation, is the primary motivation for psychedelic use across global regions. This comparative analysis of 6,379 adults from 85 countries found that psilocybin, LSD, and MDMA are the most commonly used substances. Usage patterns vary by region, with North Americans more likely to microdose and seek therapeutic benefits. Most users prefer legal, quality-controlled sources and practice infrequent, intentional use.
Abstract
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations acro...
Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration.
Nature communications – June 22, 2024
Summary
Psilocin, the active compound in magic mushrooms, alters how the brain processes threats through its effects on a key stress-response region. Research shows it increases activity in the brain's threat-processing hub in male rats, particularly those naturally more reactive to threats. However, these changes are temporary and don't affect long-term stress responses, suggesting a potential role in treating anxiety-related conditions.
Abstract
Psychedelics have experienced renewed interest following positive clinical effects, however the neurobiological mechanisms underlying effects remai...
Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology
ACS Medicinal Chemistry Letters – May 08, 2024
Summary
Psychedelics are entering a new era of therapeutic application, with innovations in pharmacology offering precise control. Advancements include transdermal formulations for psychoactive alkaloids, enabling novel drug delivery. Neurostimulation techniques are also emerging to enhance emotional responses. Psilocybin, a potent hallucinogen, is being explored via intravenous infusion for medicine. This progress in drug studies also involves the chemical synthesis of crystalline tryptamine derivatives, impacting neurotransmitter receptor influence on behavior. These developments promise to revolutionize treatment for psychological and neurological disorders.
Abstract
This Patent Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highligh...
Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hy-droxy-N,N-di-methyl-tryptamine).
Acta crystallographica. Section E, Crystallographic communications – May 01, 2024
Summary
Scientists have uncovered new details about psilocin, the active compound that gives magic mushrooms their psychedelic effects. Two distinct crystal forms of this molecule exist, each with unique structural arrangements. Using variable-temperature diffraction techniques, researchers revealed how these forms differ in their molecular bonds and shapes. Form II features an interesting self-folding structure, while Form I creates layered patterns. These findings advance our understanding of how polymorphism affects psychedelic compounds.
Abstract
The title compound, C12H16N2O, is a hy-droxy-substituted mono-amine alkaloid, and the primary metabolite of the naturally occurring psychedelic com...
Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review
Frontiers in Psychiatry – May 14, 2024
Summary
Profound subjective experiences from psychedelics like psilocybin and LSD are directly linked to specific changes in brain functional connectivity. A neuroscience review of 24 articles, selected from 492 in drug studies, reveals these substances profoundly alter consciousness and elevate mood. Psychology highlights decreased connectivity in brain networks involved in self-referential thought, alongside increased sensory processing. Such neurophysiological shifts offer a potential neural mechanism for reported mystical experiences, informing medicine's exploration of these compounds' therapeutic applications.
Abstract
Intense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various st...
New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity
Cell Death Discovery – May 01, 2024
Summary
Lasting relief from depression may stem from new understandings of brain function. Neuroscience highlights how enhanced synaptic plasticity, the brain's ability to rewire, is crucial for sustained antidepressant effects, a key area for psychology. Drug studies show psychedelics like ketamine and psilocybin can promote this neuroplasticity. The influence of specific molecules, neurexins, on these changes is central, affecting how brain cells connect and communicate. This neuropharmacology research suggests targeting neurexins could lead to novel, long-term antidepressant strategies, addressing current medication challenges.
Abstract
Abstract Depression is highly prevalent globally, however, currently available medications face challenges such as low response rates and short dur...
Use of Prescribed and Non-Prescribed Treatments for Cluster Headache in a Swedish Cohort
Brain Sciences – March 31, 2024
Summary
Psilocybin shows remarkable promise for cluster headache, with 100% (n=8) reporting it effective as an abortive medicine and 92% (n=12) finding some preventive effect. A Swedish cohort of 314 patients revealed significant undertreatment; only 46% were satisfied with their current medicine. Many faced a cluster of challenges, including 19% terminating treatments due to side effects. This highlights a critical need in Migraine and Headache Studies for diverse approaches, including physical therapy and exploring insights from Psychedelics and Drug Studies. Comprehensive physical medicine and rehabilitation, considering olfactory and sensory function, is essential.
Abstract
Background: Cluster headache (CH) is a debilitating condition, but current therapies leave CH patients in pain. The extent of this problem in Swede...
Valuing the Acute Subjective Experience
Perspectives in biology and medicine – January 01, 2024
Summary
A compelling idea emerges in **psychology**: experiences with **hallucinogens** like **psilocybin** and **MDMA** may hold intrinsic **value** (mathematics) beyond measurable therapeutic outcomes. While **medicine** and **mental health** research often focus on symptom alleviation or well-being increases, this essay challenges that narrow view. It explores how the acute subjective experience, impacting **consciousness**, could be profoundly valuable in itself. Drawing on aesthetics and **epistemology**, it offers **psychotherapists** and **social psychology** a richer understanding of these **psychedelics**, moving beyond solely outcome-based evaluations in **drug studies**.
Abstract
ABSTRACT: Psychedelics, including psilocybin, and other consciousness-altering compounds such as 3,4-methylenedioxymethamphetamine (MDMA), currentl...
The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Addiction Biology – April 01, 2024
Summary
A compelling finding in Psychedelics and Drug Studies points to 5-MeO-DMT as a rapid-acting medicine for Alcohol use disorder. Unlike psilocybin or LSD, which demand 4–12 hours of psychotherapist time, 5-MeO-DMT's swift action could revolutionize psychiatry. Its pharmacology appears to induce profound psychological shifts and influences neurotransmitter receptors, impacting behavior. This action may alleviate AUD symptoms and mood comorbidities. In the broader context of drug studies, including Cannabis and Cannabinoid Research, this short-acting psychedelic offers a promising new direction for alcohol treatment.
Abstract
Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment o...
Effects of hallucinogenic drugs on the human heart
Frontiers in Pharmacology – February 02, 2024
Summary
Beyond their known central nervous system effects, hallucinogens like Lysergic acid diethylamide (LSD) and Psilocybin also profoundly impact heart function. Pharmacology reveals these psychedelics, often products of intricate chemical synthesis and alkaloids, stimulate serotonin receptors, influencing heart rate (chronotropic action) and contraction strength. This includes substances such as Ergotamine and other Lysergic acid derivatives. Understanding this complex chemistry is vital for medicine and drug studies, highlighting a significant neurotransmitter receptor influence on behavior and physiology.
Abstract
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation ...
Psychedelic Microdosing among Young Adults from Southern California
Journal of Psychoactive Drugs – February 10, 2024
Summary
Nearly one in five young adults attempting psychedelic microdosing actually take standard, psychoactive doses, risking adverse effects. Among 2,396 young adults, only 3% (74 individuals) had ever microdosed, despite 12% awareness. Psilocybin (70%) and lysergic acid diethylamide (57%) were the most common hallucinogens. This underscores the need for Medicine, Psychiatry, and Psychology to provide clear guidance on these chemical synthesis and alkaloids, for both Clinical Psychology and broader Psychedelics and Drug Studies.
Abstract
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, an...
Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways
Ageing Research Reviews – February 01, 2024
Summary
A compelling finding in Neuroscience reveals psychedelics like Psilocybin, DMT, and LSD hold significant promise for treating Alzheimer's disease, a devastating form of dementia. These powerful chemical compounds, with a rich historical context, modulate neurotransmitter receptors to enhance neural plasticity and combat disease progression. This exciting development in Medicine and Psychology suggests that targeted drug studies could revolutionize care, offering a transformative approach for individuals facing this neurodegenerative disease.
Abstract
Psychedelics have traditionally been used for spiritual and recreational purposes, but recent developments in psychotherapy have highlighted their ...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Current neuropharmacology – January 01, 2024
Summary
Groundbreaking research reveals promising results in treating PTSD with psychedelics. Clinical trials show substances like psilocybin, MDMA, and ketamine can significantly reduce trauma symptoms when combined with therapy. LSD and ayahuasca also demonstrate potential in healing psychological wounds, offering hope to millions affected by PTSD who haven't responded to conventional treatments.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 mil...
Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
The primary care companion for CNS disorders – January 16, 2024
Summary
Regular microdosing of psychedelics like LSD and psilocybin shows promise for mental wellness, with users reporting improved mood and focus. Analysis of multiple studies reveals consistent benefits for daily functioning, though some participants experienced mild discomfort. Positive expectations often aligned with better outcomes in controlled trials.
Abstract
Objective: To investigate the relationship between psychedelic microdosing and its effects on mental health, aiming to understand if microdosing ca...
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Ochsner Journal – January 01, 2023
Summary
Psychedelics offer a promising new avenue for treating anxiety disorders. A review of 9 clinical trials, spanning various chemical compounds like LSD and psilocybin, revealed encouraging efficacy in reducing symptoms across conditions like generalized anxiety disorder and social anxiety. Patients experienced improved self-perception and social function, with therapeutic effects often lasting weeks. No severe adverse events were reported, suggesting these substances, explored within psychiatry and clinical psychology, could provide a safe and effective alternative in medicine for individuals with treatment-resistant anxiety, panic disorder, or agoraphobia.
Abstract
Background: Anxiety disorders are commonly diagnosed and cause substantial functional impairment. A mixture of pharmacologic and psychosocial treat...
Biological studies of clavine alkaloids targeting CNS receptors
Frontiers in Psychiatry – November 21, 2023
Summary
Potent clavine alkaloids, widely present through plant and fungal interactions, are surprisingly underexplored compared to well-known psychedelics like psilocybin and lysergic acid diethylamide. Their unique pharmacology and biology, influencing various brain receptors, offer vast potential for drug studies. Exploring their chemical synthesis and alkaloids could uncover novel hallucinogen compounds. This neuroscience-focused work highlights opportunities to expand the therapeutic range beyond current lysergic acid derivatives, revolutionizing our understanding of psychedelic action and future drug development.
Abstract
In contrast to well established psychedelics such as lysergic acid diethylamide (LSD) and psilocybin, ergot alkaloids of the clavine subclass have ...
Classical psychedelics in psychiatry - renaissance of interest and therapeutic perspectives.
Psychiatria polska – June 30, 2023
Summary
Psychedelics like LSD and psilocybin are showing remarkable promise in modern psychiatry, reviving therapeutic approaches from traditional healing practices. Recent clinical trials demonstrate these substances' potential as breakthrough pharmacotherapy options for treating depression, anxiety, and addiction. When combined with professional therapy, psychedelics appear safe and effective, offering hope for patients who haven't responded to conventional treatments.
Abstract
Substances that change the states of consciousness have been used in the therapeutics of traditional cultures for hundreds of years. In the Western...
Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Chemical Reviews – November 30, 2023
Summary
Psychedelics, including psilocybin and Lysergic acid diethylamide, are demonstrating significant promise in drug studies as rapid-acting antidepressants. These compounds influence behavior by engaging the serotonin 5-HT receptor. The core challenge in pharmacology is to refine their chemistry through chemical synthesis of novel alkaloids. This involves understanding functional selectivity at the 5-HT2A receptor to develop safer drugs that retain therapeutic benefits without hallucinogen effects. This Neurotransmitter Receptor Influence on Behavior research aims to unlock their full potential.
Abstract
Psychedelics make up a group of psychoactive compounds that induce hallucinogenic effects by activating the serotonin 2A receptor (5-HT2AR). Clinic...
A Brief Historical Overview of Psychedelic Research.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
In the 1950s, researchers discovered that psychedelics like LSD and psilocybin could profoundly impact mental health treatment. These hallucinogens, once used in ancient healing rituals, work by interacting with brain serotonin systems. Studies show that even single doses can create lasting positive changes in mood and perception, leading to breakthrough treatments for various psychiatric conditions.
Abstract
Classical serotonergic psychedelics such as lysergic acid diethylamide or the naturally occurring compounds psilocybin and mescaline produce profou...
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Journal of Psychopharmacology – November 16, 2023
Summary
Measuring the profound shifts in consciousness induced by psychedelics like psilocybin, ayahuasca, and lysergic acid diethylamide is surprisingly inconsistent, hindering clinical psychology. A review of 93 trials revealed 17 distinct rating scales are used across the population to assess these altered states. The Hallucinogen Rating Scale is among the five most utilized. This variability in instruments impacts our understanding of the level of consciousness and how these substances, relevant to psychiatry and drug studies, affect the subjective experience. Standardized measurement is crucial.
Abstract
Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produ...
The psychedelic effects of cannabis: A review of the literature
Journal of Psychopharmacology – November 10, 2023
Summary
Compellingly, high-Delta-9-tetrahydrocannabinol (THC) Cannabis may induce psychedelic effects, challenging Psychiatry. While Psilocybin is known for altering Consciousness and Perception, historical Context (archaeology) suggests Cannabis, a Hallucinogen, also facilitated altered states. Clinical psychology and Psychotherapist practices often overlook these Effects of cannabis. Relevant to Psychedelics and Drug Studies and Cannabis and Cannabinoid Research, specific doses and settings are crucial, potentially revealed by Biochemical Analysis and Sensing Techniques. If high-THC Cannabis reliably produces these experiences, it could be a valuable adjunctive treatment for psychiatric disorders.
Abstract
Cannabis and classic psychedelics are controlled substances with emerging evidence of efficacy in the treatment of a variety of psychiatric illness...
Psychedelics for treatment resistant depression: are they game changers?
Expert Opinion on Pharmacotherapy – November 10, 2023
Summary
Psychedelic therapy is creating a paradigm shift in Medicine for Treatment-resistant depression. Psilocybin, a potent alkaloid, shows extraordinary antidepressant promise. This compound, often from chemical synthesis, rapidly influences neurotransmitter receptors, with some individuals experiencing benefits sustained for at least 3 months. This could transform Psychiatry, offering psychotherapists a novel approach to severe Depression and potentially easing its economic burden. Ongoing drug studies are exploring these powerful compounds, providing hope where traditional treatments often fail.
Abstract
Psychedelic therapy has created a paradigm shift in the treatment of TRD, as it can maximize therapeutic benefits and minimize potential risks. Psi...
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.
Molecular psychiatry – January 01, 2024
Summary
Combining psychedelics with specific brain receptor modulators may enhance mental health treatment while reducing unwanted effects. New findings show that psilocybin and NMDA receptor compounds like D-serine work together to boost brain plasticity and mood improvement. This dual approach could offer more effective, safer treatment options for depression and other mental health conditions.
Abstract
Modern research data suggest a therapeutic role for serotonergic psychedelics in depression and other neuropsychiatric disorders, although psychoto...
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.
The Journal of neuroscience : the official journal of the Society for Neuroscience – November 08, 2023
Summary
Psychedelic drugs like psilocybin and LSD work through multiple brain pathways, not just the well-known serotonin receptor system. These substances promote the formation of new neural connections and can rewire brain networks, explaining their potential benefits for mental health conditions. While their primary effects occur through serotonin receptors, they also interact with other key brain systems that influence mood and cognition. Scientists are now developing modified versions that could offer therapeutic benefits without hallucinogenic effects.
Abstract
Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects ...
The possible place for psychedelics in pharmacotherapy of mental disorders.
Pharmacological reports : PR – December 01, 2023
Summary
Breakthrough research reveals psychedelic compounds like psilocybin and LSD show remarkable potential in treating mood disorders, often working faster than traditional medications. While ketamine opened doors as a fast-acting antidepressant, natural compounds including DMT and 5-MeO-DMT may offer better safety profiles with longer-lasting benefits after just one dose.
Abstract
Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting...
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Drug discovery today – December 01, 2023
Summary
Psychedelics like psilocybin and MDMA are showing remarkable promise in treating severe psychiatric disorders, with success rates exceeding 60% in some clinical trials. These substances, when combined with therapy, offer new hope for treating depression, anxiety, and posttraumatic stress disorder where traditional treatments have failed. Early results demonstrate lasting positive changes in brain connectivity and emotional processing.
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic ag...
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports – October 24, 2023
Summary
Psychedelics, powerful hallucinogens like psilocybin, Lysergic acid diethylamide, and mescaline, are re-emerging in medicine for psychiatry, improving mood and psychological well-being. Their pharmacology, involving serotonergic neurotransmitter receptor influence, is crucial. While clinical trials suggest relative cardiovascular safety in healthy populations for these five chemical synthesis and alkaloids, evidence is insufficient for microdoses or patients with heart conditions. Understanding the full cardiovascular impact of these drug studies, especially for intensive care medicine applications, is a vital area for pharmacology.
Abstract
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychi...